Siemens Medical Systems of Iselin, NJ, has received Food and Drug Administration 510(k) clearancefor an upgrade package that brings faster echo-planar imagingrise times to its 1.5-tesla Magnetom Vision MRI scanner. The packagewill be available as a free
Siemens Medical Systems of Iselin, NJ, has received Food and Drug Administration 510(k) clearancefor an upgrade package that brings faster echo-planar imagingrise times to its 1.5-tesla Magnetom Vision MRI scanner. The packagewill be available as a free upgrade to Vision scanners in thefield. It improves EPI rise times to 600 microseconds, comparedto 1200 microseconds on Vision's previous echo-planar sequence,which began shipping in November, according to Michael Sweitzer,product manager for MRI.
Rise times are the speed at which a scanner's gradients risefrom zero to maximum amplitude, which in Vision's case is fromzero to 25 mtesla/meter. Faster rise times help avoid respiratoryand blood-flow artifacts and are expected to improve Vision'sutility in future applications such as diffusion-perfusion imagingand functional imaging. Siemens is working on a hardware upgradeto Vision that will bring rise times down to 300 microseconds,Sweitzer said.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.